Day One Biopharmaceuticals Inc
DAWN
Mkt cap
$656.83M
EV/Sales
2.91
P/E ratio
—
FY2025 Revenue
$158.18M
EPS (9mo ended 2025-09-30)
−$0.83
Gross Margin (FY2025)
—
Profit Margin (FY2025)
−67.85%
Beta
−1.30
Div yield
—
Sector
Healthcare
What matters now, from SEC filings and analyst ratings
Takeaway
A takeaway appears here once the latest filing has been analyzed.
Analysts
Sector-relative grades for valuation, growth, profitability, momentum and revisions
Form 4 trades, last 90 days
No open-market insider buy or sell of DAWN since Aug 20, 2026.
Latest SEC filings
Source: SEC EDGAR · Latest filing Jan 12, 2026
Latest stored headlines
Day One Biopharmaceuticals Inc (DAWN) is a biotechnology company listed on US.
Latest reported DAWN revenue for 2025-12-31 was $158.2M. Net income was -$107.3M. Revenue was up 20.6% from 2024-12-31 to 2025-12-31. DAWN currently screens at market cap $656.8M.
Use this DAWN research hub for sector, financials, and filings — not a live tape.
Latest cached year on this hub. Full DAWN income, balance, and cash tables.
Day One Biopharmaceuticals Inc (DAWN) is a biotechnology company in the Healthcare sector.
Latest cached Day One Biopharmaceuticals Inc (DAWN) revenue for Dec 31, 2025 was $158.2M. Net income was -$107.3M. Statements: https://lician.com/financials/dawn
Day One Biopharmaceuticals Inc (DAWN) market capitalization is $656.8M on the latest cached snapshot.
The latest cached DAWN filing is 8-K · Jan 12, 2026. Filings: https://lician.com/sec/dawn
SEC filings · latest fiscal year FY2025
Free shows the newest 2 years. FY2021–FY2023 on Pro
+20.6%
Revenue growth year over year
Institutional holders from SEC 13F filings
10-Q results and the earnings calendar
Revenue and EPS are GAAP diluted from the 10-Q. Beat or miss compares the calendar's actual with its estimate on the same basis (adj.), or revenue with the revenue estimate.